By Katherine Hamilton

Korro Bio plans to reduce its workforce by 34% after pausing its licensing partnership with Novo Nordisk.

The Cambridge, Mass., biopharmaceutical company said Wednesday the job cuts are part of a strategic restructuring. Korro had 104 full-time employees as of December 2024.

Korro expects to incur a one-time charge of $2.4 million related to severance, benefits and termination costs, which the company expects to recognize before the end of the year.

The job cuts come as Korro and Novo Nordisk have agreed to pause their licensing agreement for 12 months. Under the agreement, which was signed in September 2024, Novo Nordisk had an exclusive global license to research, develop and sell certain cardiometabolic products developed by Korro.

During the pause, all research and development activities under the agreement will be suspended, Korro said. Korro is also winding down its research and development activities in connection with the agreement.

Korro is aiming to extend its cash runway into the second half of 2027 to deliver clinical data for KRRO-121, a treatment designed to help patients with hyperammonemia, which is a condition where there is too much ammonia in the blood.

Korro's chief medical Officer Olukemi Olugemo also resigned. Its chief financial officer stepped down in October.

- - 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

November 12, 2025 17:03 ET (22:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.